Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lukas Owens

Showing results (1-10 of 12) with videos related to

Pageof 2
Sort By:
CA: a Cancer Journal for Clinicians|September 29, 2025
Learning from prostate cancer statisticsRuth Etzioni, Lukas Owens
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|April 27, 2022
Stage Shift as an Endpoint in Cancer Screening Trials: Implications for Evaluating Multicancer Early Detection TestsLukas Owens, Roman Gulati, Ruth Etzioni
JNCI Cancer Spectrum|October 23, 2024
Trends in age and prostate-specific antigen at prostate cancer diagnosis between 2010 and 2019Lukas Owens, Ojas Brahme, Roman Gulati, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|March 19, 2026
Cost-Effectiveness Analysis of <sup>177</sup>Lu-PSMA-617 Versus Cabazitaxel in Metastatic Castration-Resistant Prostate Cancer from a U.S. Health Care PerspectiveKemal C Gogebakan, Natalia Kunst, Alireza Ghodsi, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|June 1, 2023
Short-term Endpoints for Cancer Screening Trials: Does Tumor Subtype Matter?Lukas Owens, Kemal Caglar Gogebakan, Usha Menon, et al.
Human Pathology|April 9, 2024
Enhancing upper tract urothelial carcinoma diagnosis: Utility of cytokeratin 17 and CK20/CD44/p53 immunohistochemical panelTrent Irwin, Amelia W Donlan, Lukas Owens, et al.
Journal of the National Cancer Institute|March 5, 2025
Trends in Young-Onset Cancer Incidence: A Modeling PerspectiveLukas Owens, Allison Fung, Jonathan Shuhendler, et al.
JAMA Network Open|March 12, 2024
Survival in Patients With De Novo Metastatic Prostate CancerMartin W Schoen, R Bruce Montgomery, Lukas Owens, et al.
JAMA Network Open|October 9, 2025
Clinical Significance of a Multicancer Screening Trial With Stage-Based End PointsKemal Caglar Gogebakan, Jane Lange, Lukas Owens, et al.
Journal of the National Cancer Institute|March 30, 2026
Measuring and defining screening benefit in a new era of cancer early detectionRuth Etzioni, Kemal Gogebakan, Roman Gulati, et al.
Pageof 2

Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
CA: a Cancer Journal for Clinicians|September 29, 2025
Learning from prostate cancer statisticsRuth Etzioni, Lukas Owens
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|April 27, 2022
Stage Shift as an Endpoint in Cancer Screening Trials: Implications for Evaluating Multicancer Early Detection TestsLukas Owens, Roman Gulati, Ruth Etzioni
JNCI Cancer Spectrum|October 23, 2024
Trends in age and prostate-specific antigen at prostate cancer diagnosis between 2010 and 2019Lukas Owens, Ojas Brahme, Roman Gulati, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|March 19, 2026
Cost-Effectiveness Analysis of <sup>177</sup>Lu-PSMA-617 Versus Cabazitaxel in Metastatic Castration-Resistant Prostate Cancer from a U.S. Health Care PerspectiveKemal C Gogebakan, Natalia Kunst, Alireza Ghodsi, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|June 1, 2023
Short-term Endpoints for Cancer Screening Trials: Does Tumor Subtype Matter?Lukas Owens, Kemal Caglar Gogebakan, Usha Menon, et al.
Human Pathology|April 9, 2024
Enhancing upper tract urothelial carcinoma diagnosis: Utility of cytokeratin 17 and CK20/CD44/p53 immunohistochemical panelTrent Irwin, Amelia W Donlan, Lukas Owens, et al.
Journal of the National Cancer Institute|March 5, 2025
Trends in Young-Onset Cancer Incidence: A Modeling PerspectiveLukas Owens, Allison Fung, Jonathan Shuhendler, et al.
JAMA Network Open|March 12, 2024
Survival in Patients With De Novo Metastatic Prostate CancerMartin W Schoen, R Bruce Montgomery, Lukas Owens, et al.
JAMA Network Open|October 9, 2025
Clinical Significance of a Multicancer Screening Trial With Stage-Based End PointsKemal Caglar Gogebakan, Jane Lange, Lukas Owens, et al.
Journal of the National Cancer Institute|March 30, 2026
Measuring and defining screening benefit in a new era of cancer early detectionRuth Etzioni, Kemal Gogebakan, Roman Gulati, et al.
Pageof 2